Biopharma Firm Veru Plunges Following Equity Offering Announcement
Published on 10/30/2025 at 07:04 | Redaktion boerse-global.de
Shares of Veru experienced severe volatility after the company revealed plans to raise capital through a public securities offering. The biopharmaceutical company’s proposal to issue common stock alongside Series A and Series B convertible notes triggered an immediate sell-off among concerned investors.
The financial markets responded swiftly to Veru’s capital raising plans. During the latest trading session, the company’s stock price collapsed by 3.29 percent to settle at $3.53, having opened at $3.67. The trading range proved even more dramatic, spanning a full 7.00 percent between $3.50 and $3.745.
This recent decline represents just part of a broader downward trend. Over seven of the past ten trading days, Veru shares have recorded losses, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
